alexa Abstract | Promising SINEs in the Treatment of Pancreatic Cancer

JOP. Journal of the Pancreas
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Pancreatic cancer remains a deadly disease in urgent need of newer therapeutic modalities. Pancreatic tumors are very heterogeneous and carry alterations in many critical pathways (i.e. harboring a robust biological network) rendering the design of therapy against a single pathway unrealistic. The disease requires a broad form of therapy that can target the activation of multiple tumor suppressor proteins simultaneously. It has been consistently shown in pancreatic cancer biopsies that there is an over-expression of the nuclear exporter protein exportin 1 also known as Chromosome maintenance region 1. Nuclear exporter protein exportin 1 is recognized to export major nuclear residing tumor suppressor proteins causing their functional inactivation through their mislocalization to the cytoplasmic compartment. This makes exportin 1 an attractive therapeutic target in pancreatic cancer. Supporting this we have clearly demonstrated that targeted inhibition of exportin 1 by our specific inhibitors of nuclear export can restore the function of multiple tumor suppressor proteins leading the pancreatic cancer cell death and tumor inhibition in orthotopic models. Additionally, studies have demonstrated that specific inhibitors of nuclear export synergize with gemcitabine and nab-paclitaxel leading to enhanced pancreatic cancer growth inhibition, apoptosis, and disintegration of cancer stem cell mimicking spheroids. Collectively these studies have lead to a Phase Ib/II clinical evaluation of specific inhibitors of nuclear export with GEM and nab-paclitaxel in patients with metastatic pancreatic cancer ( Identifier: NCT02178436). In this mini-review we highlight the promising specific inhibitors of nuclear export in pancreatic cancer.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Asfar S Azmi Yosef Landesman Erkan Baloglu Amro Aboukameel Irfana Muqbil Michael Kauffman Philip A Philip Sharon Shacham Ramzi M Mohammad


Active Transport, Cell Nucleus, Combined Modality Therapy, Drug Resistance, Pancreatic Neoplasms

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version